Â鶹ŮÓÅ

The clinical trials for new Alzheimer’s disease treatment drugs — which researchers believe will slow the course of the disease over time — offer hope to thousands of people who have the disease. Unfortunately, the trials failed to include the very population that made progress on Alzheimer’s treatments possible — those with Down syndrome. (Hampus Hillerstrom and Jo Ann Simons, 9/18)

PrEP is a medication—either in the form of a pill or more recently an injection—that people without HIV can take to reduce the risk of getting HIV by up to 99 percent. At the same time, Democrats here at home re-introduced the PrEP Access and Coverage Act, which would expand access to HIV prevention medicines. As a researcher studying the health impacts of mass incarceration, any measure to expand PrEP access must prioritize people within our country's prisons and jails. (Tyler Harvey, 9/15)

Apellis Pharmaceuticals has been slowly rebounding from an unjustified safety scare related to its approved treatment for a common type of vision loss. Now, a competing medicine from Astellas, also recently approved, may have stumbled, which could further boost Apellis’ business outlook — and its stock price. (Adam Feuerstein, 9/20)